Research

Hormonal

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACEs) and all-cause mortality in patients with type 2 diabetes, independent of glycemic control, through anti-inflammatory and plaque-stabilizing mechanisms.

If you have type 2 diabetes and high cardiovascular risk, GLP-1RAs like semaglutide or liraglutide can significantly reduce your risk of heart attack, stroke, and death. This benefit comes from stabilizing plaque and reducing inflammation, not just lowering blood sugar. Discuss these options with your doctor, especially if you have existing heart disease.

GoodSupportsHIGH confidence
GLP-1RAs are a new class of drugs, belonging to the armamentarium to fight type 2 DM, that have shown robust reductions in atherosclerotic events and all-cause mortality in all studies... GLP-1RAs operate independently of T2DM-induced hypoglycemic effects and positively impact the cardiovascular system.
Dalgisio Lecis et al. · Biomolecules · 2023

Why this rating

Based on multiple large randomized controlled trials (LEADER, SUSTAIN-6, etc.) cited in the review.

Source

Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?

Dalgisio Lecis et al. · Biomolecules · 2023

DOI 10.3390/biom13121695

narrative_reviewCited 18×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →